- Home
- ADAC vs TARA Comparison
ADAC vs TARA Comparison
Compare ADAC & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.16
Company Overview
Basic Information| Metric | ADAC | TARA |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.2M | 292.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADAC | TARA |
|---|---|---|
| Price | $9.93 | $5.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 35.6K | ★ 578.0K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $2.77 |
| 52 Week High | $9.99 | $7.82 |
Technical Indicators
Market Signals| Indicator | ADAC | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 46.20 |
| Support Level | $9.91 | $4.92 |
| Resistance Level | $9.99 | $5.53 |
| Average True Range (ATR) | 0.01 | 0.27 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 29.25 |
Price Performance
Historical Comparison ADAC
TARA
About ADAC American Drive Acquisition Company Class A Ordinary Shares
American Drive Acquisition Co is a blank check company.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.